Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Sunnere hjemmemåltider for vordende mødre (Her HOME)

12. oktober 2026 oppdatert av: Gareth R. Dutton PhD, University of Alabama at Birmingham

Bruk av hjemmeleverte måltider for å redusere overdreven vektøkning i svangerskapet for høyrisikokvinner

This study is being done to test the feasibility, acceptability, and preliminary efficacy of a meal delivery intervention for managing gestational weight gain among pregnant women with overweight or obesity.

Studieoversikt

Status

Fullført

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Faktiske)

35

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forente stater, 35294
        • University of Alabama at Birmingham

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

Inclusion Criteria:

  • Age ≥ 18 years
  • Gestational age ≤ 15 weeks as assessed by ultrasound
  • Body mass index (BMI) ≥ 25 kg/m2
  • Singleton viable pregnancy
  • Receiving care and planning to deliver at UAB
  • Residing within the delivery radius of the meal delivery company
  • Wi-Fi or Bluetooth Internet connection in home (for digital Wi-Fi enabled study scale)

Exclusion Criteria:

  • Self-reported major health conditions (e.g., heart disease, cancer, renal disease, and Type 1 or Type 2 diabetes)
  • Current substance abuse
  • Current treatment for serious psychiatric disorder (schizophrenia, bipolar disorder)
  • Known fetal anomaly
  • Planned termination of pregnancy
  • Past history or current diagnosis of anorexia or bulimia
  • Current use of one or more of the following medications:
  • Metformin
  • Systemic steroids
  • Antipsychotic agents
  • Anti-seizure medications or mood stabilizers that would be expected to have a significant impact on body weight
  • Medications for ADHD including amphetamines and methylphenidate
  • Any teratogenic agent Class D
  • Participation in another dietary and/or weight management intervention during pregnancy
  • Unwilling or unable to consume prepared meals delivered weekly
  • Unable to understand and communicate in verbal and written English

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Intervention

Meal delivery intervention with brief behavioral support.

10 healthy, home-delivered meals per week + brief weekly remote behavioral support

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Weight From First to Last Prenatal Visit
Tidsramme: First prenatal visit (<=15 weeks gestation), last prenatal visit (35+ weeks gestation)

Weight measured at the first and last prenatal visits will be retrieved from medical records for all participants and used to calculate total weight change from the first to the last prenatal visit (i.e., gestational weight gain).

First prenatal visit (<=15 weeks gestation), last prenatal visit (35+ weeks gestation)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Food Insecurity
Tidsramme: baseline (12-15 weeks gestation), (35-36 weeks gestation)

Determined using the 18-item United States (US) Household Food Security Survey Module based on the previous 30 days. Adult food security scores range from 0 to 10, with lower values indicating greater food security. Change in Food Security was calculated as food security score at follow up minus score at baseline, with negative values indicating an increase in food security from baseline to follow up.

baseline (12-15 weeks gestation), (35-36 weeks gestation)
Change in Perceived Stress
Tidsramme: baseline (12-15 weeks gestation), (35-36 weeks gestation)

Determined using the 10-item Perceived Stress Scale (PSS-10) based on the last month. PSS-10 scores range from 0 to 40, with higher scores representing higher levels of perceived stress. Change in Perceived Stress score was calculated as score at follow up minus score at baseline, with positive values indicating an increase in perceived stress score from baseline to follow up.

baseline (12-15 weeks gestation), (35-36 weeks gestation)
Change in Participant Satisfaction With Diet
Tidsramme: baseline (12-15 weeks gestation), (35-36 weeks gestation)

To assess satisfaction with the study intervention, the 28-item Diet Satisfaction Questionnaire (DSAT-28) will be used in which participants respond to 28 statements using a 5-point Likert scale. Responses to all 28-items are averaged to produce a total diet satisfaction score (designed to reflect satisfaction as it relates to following a weight-management diet) ranging from 1-5. Subscale scores for Cost Factor (reflects financial cost of the diet) and Planning & Preparation Factor (reflects amount of time and effort spent in planning and preparing) will also be calculated and range from 1-5. For the overall diet satisfaction score and subscale scores, higher scores represent greater satisfaction. Changes in overall diet satisfaction, as well as changes in subscale scores for Cost Factor and Planning & Preparation Factor are calculated as score at follow up minus score at baseline, with positive values indicating an increase in satisfaction) from baseline to follow up.

baseline (12-15 weeks gestation), (35-36 weeks gestation)
Proportion of Women Exceeding Institute of Medicine Gestational Weight Gain Guidelines
Tidsramme: First prenatal visit (<=15 weeks gestation), last prenatal visit (35+ weeks gestation)

Weight at the first prenatal visit will be subtracted from weight at the last prenatal visit. Women will be categorized as exceeding 2009 Institute of Medicine gestational weight gain guidelines if the difference is > 11.5 kg gain for women with overweight or >9 kg for women with obesity at the first prenatal visit.

First prenatal visit (<=15 weeks gestation), last prenatal visit (35+ weeks gestation)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Gareth Dutton, PhD, University of Alabama at Birmingham
  • Hovedetterforsker: Camille Worthington, PhD, University of Alabama at Birmingham

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

9. august 2023

Primær fullføring (Faktiske)

14. oktober 2025

Studiet fullført (Faktiske)

31. oktober 2025

Datoer for studieregistrering

Først innsendt

25. oktober 2022

Først innsendt som oppfylte QC-kriteriene

28. oktober 2022

Først lagt ut (Faktiske)

4. november 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

4. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

De-identified individual participant data (IPD) that underlie the results reported in a publication will be made available upon request beginning 9 months and ending 36 months following article publication. The research team will keep a record of all individuals and/or research teams who request and receive a copy of the project data. Interested investigators will be asked to submit a document indicating the specific aims of the analyses, the analytic plan, available resources for completing the proposed project, proposed timeline, and goals (i.e., manuscripts, presentations, and/or grant applications). The PI and research team will review these requests to determine whether the proposed analyses constitute an innovative and significant exploration of the data, whether the proposed team has sufficient resources to complete the request, and whether data will be adequately protected and managed.

IPD-delingstidsramme

Data requests can be submitted starting 9 months after publication of results and ending 36 months following article publication.

Tilgangskriterier for IPD-deling

Access to IPD stripped of all HIPAA identifiers (except age) for this study can be requested by qualified researchers engaging in independent scientific research whose proposed research has received Institutional Review Board approval, and will be provided following review and approval of a research proposal and timeline, statistical analysis plan, and goals (e.g., manuscripts, presentations, grant applications). The Principal Investigator (PI) and research team will review these requests to determine whether the proposed analyses constitute an innovative and significant exploration of the data, whether the proposed team has sufficient resources to complete the request, and whether data will be adequately protected and managed. Based on institutional policies, execution of a Data Sharing Agreement may be required prior to sharing of IPD. IPD requests can be made to the MPIs at gdutton@uabmc.edu or cschneid@uab.edu.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • ICF

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere